It has been generally accepted that Gamma Knife surgery (GKS) is an effective primary or adjunct treatment for patients with 1–4 metastases to the brain. The number of studies detailing the use of GKS for 5 or more brain metastases, however, remains minimal. The aim of the current retrospective study was to elucidate the utility of GKS in patients with 5–15 brain metastases.
Patients were chosen for GKS based on prior MRI of these metastatic lesions and a known primary cancer diagnosis. Magnetic resonance imaging was used post-GKS to assess tumor control; patients were also followed up clinically. Overall survival (OS) from the date of GKS was used as the primary end point. Statistical analysis was performed to identify prognostic factors related to OS.
Between 2003 and 2012, 96 patients were treated for a total of 704 metastatic brain lesions. The histology of these lesions varied among non–small cell lung cancer (NSCLC), breast cancer, melanoma, renal cancer, and other more rare carcinomas. At the initial treatment, 18 of the patients (18.8%) were categorized in Recursive Partitioning Analysis (RPA) Class 1 and 77 (80.2%) in RPA Class 2; none were in RPA Class 3. The median number of treated lesions was 7 (mean 7.13), and the median planned treatment volume was 6.12 cm3 (range 0.42–57.83 cm3) per patient. The median clinical follow-up was 4.1 months (range 0.1–40.70 months). Actuarial tumor control was calculated to be 92.4% at 6 months, 84.8% at 12 months, and 74.9% at 24 months post-GKS. The median OS was found to be 4.73 months (range 0.4–41.8 months). Multivariate analysis demonstrated that RPA class was a significant predictor of death (HR = 2.263, p = 0.038). Number of lesions, tumor histology, Graded Prognostic Assessment score, prior whole-brain radiation therapy, prior resection, prior chemotherapy, patient age, patient sex, controlled primary tumor, extracranial metastases, and planned treatment volume were not significant predictors of OS.
In patients with 5–15 brain metastases at presentation, the number of lesions did not predict survival after GKS; however, the RPA class was predictive of OS in this group of patients. Gamma Knife surgery for such patients offers an excellent rate of local tumor control.
Abbreviations used in this paper:GKS = Gamma Knife surgery; GPA = Graded Prognostic Assessment; JLGK = Japan Leksell Gamma Knife; KPS = Karnofsky Performance Status; NSCLC = non–small cell lung cancer; OS = overall survival; PTV = planned treatment volume; RECIST = Response Evaluation Criteria in Solid Tumors; RPA = Recursive Partitioning Analysis; RTOG = Radiation Therapy Oncology Group; UVA = University of Virginia; WBRT = whole-brain radiation therapy.
AndrewsDWScottCBSperdutoPWFlandersAEGasparLESchellMC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet363:1665–16722004
ChangWSKimHYChangJWParkYGChangJH: Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? Clinical article. J Neurosurg113:Suppl73–782010
GrandhiRKondziolkaDPanczykowskiDMonacoEAIIIKanoHNiranjanA: Stereotactic radiosurgery using the Leksell gamma knife Perfexion unit in the management of patients with 10 or more brain metastases. Clinical article. J Neurosurg117:237–2452012
KondziolkaDPatelALunsfordLDKassamAFlickingerJC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys45:427–4341999
LinskeyMEAndrewsDWAsherALBurriSHKondziolkaDRobinsonPD: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol96:45–682010
MinnitiGSalvatiMMuniRLanzettaGOstiMFClarkeE: Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. Anticancer Res30:3055–30612010
RadesDBohlenGPluemerAVeningaTHanssensPDunstJ: Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer109:2515–25212007
SanghaviSNMiranpuriSSChappellRBuattiJMSneedPKSuhJH: Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys51:426–4342001
SchögglAKitzKReddyMWolfsbergerSSchneiderBDieckmannK: Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir (Wien)142:621–6262000
SerizawaTHiraiTNaganoOHiguchiYMatsudaSOnoJ: Gamma knife surgery for 1–10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. J Neurooncol98:163–1672010
SerizawaTYamamotoMSatoYHiguchiYNaganoOKawabeT: Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional prospective study. Clinical article. J Neurosurg113:Suppl48–522010
SheehanJPYenCPNguyenJRaineyJADassoulasKSchlesingerDJ: Timing and risk factors for new brain metastasis formation in patients initially treated only with Gamma Knife surgery. Clinical article. J Neurosurg114:763–7682011
SneedPKSuhJHGoetschSJSanghaviSNChappellRBuattiJM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys53:519–5262002
SperdutoPWBerkeyBGasparLEMehtaMCurranW: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys70:510–5142008
YamamotoMSatoYSerizawaTKawabeTHiguchiYNaganoO: Subclassification of recursive partitioning analysis class II patients with brain metastases treated radiosurgically. Int J Radiat Oncol Biol Phys83:1399–14052012